Angiomax - (250 mg/Vial; Injectable, Intravenous)

Generic Name	Bivalirudin	**Innovator**	Medicines co.
Dosage	250 mg/Vial; Injectable, Intravenous	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	More Than 5
Other ANDA developers	None	**Tentative Approvals**	Less Than 5
Final Approvals	More Than 5	**Generic Launches**	More Than 5
Indication	Indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.